Formal inauguration of a commercial-scale CMO campus in Sangareddy consolidates India’s ambition to become a global hub for cell and gene therapy manufacturing.
A new chapter in India’s pharmaceutical landscape opened on June 4, 2026, when Aurobindo Pharma formally inaugurated TheraNym Biologics — a ₹1,200-crore Contract Manufacturing Organisation (CMO) facility at Sangareddy, on the northern periphery of the Hyderabad Pharma City cluster. The scale and technical specification of the facility signal an unambiguous strategic intent: to position India as a credible, commercial-grade manufacturing destination not merely for generic small molecules but for the most complex and high-value category in modern medicine — biologics, vaccines, and advanced cell and gene therapies.
TheraNym is structured as a dedicated CMO campus, meaning its manufacturing capacity is offered as a service to pharmaceutical and biotechnology innovators worldwide who require GMP-compliant production at clinical and commercial scale without building proprietary manufacturing infrastructure. This model — well-established in Europe and the United States through organisations such as Lonza, Samsung Biologics, and Catalent — has remained underdeveloped in India relative to the country’s formulation and API manufacturing strength. TheraNym’s inauguration addresses that gap directly.
Capability Profile: What the Facility Can Produce
The facility’s production scope spans three distinct but interconnected therapeutic modalities. The first is conventional biologics manufacturing — recombinant proteins, monoclonal antibodies, fusion proteins, and biosimilars — produced through mammalian cell culture (CHO cell lines) and microbial fermentation systems in bioreactor volumes appropriate for commercial supply. The second is vaccine manufacturing, encompassing both recombinant protein-based vaccines and, critically, mRNA vaccine platforms — a strategic priority in the post-COVID global health security architecture.
The third and most technically demanding category is cell and gene therapy (CGT) manufacturing. This encompasses autologous and allogeneic CAR-T cell therapies for oncology, viral vector production (adeno-associated virus and lentiviral vectors) for gene therapy programmes, and ex-vivo cell engineering processes. CGT manufacturing is characterised by extreme process complexity, patient-specific logistics, and regulatory scrutiny that make it among the most difficult operations in the pharmaceutical industry to establish and sustain at commercial scale. TheraNym’s declared capacity to operate in this space from inauguration day — rather than as a future build-out — is the most significant technical claim of the facility.
Strategic Significance for India and the Region
India’s pharmaceutical industry has long been described as the world’s pharmacy for generics. TheraNym represents a deliberate and capital-intensive effort to extend that identity up the value chain into advanced therapeutics — products that carry price points and margins orders of magnitude higher than generics, and that serve patient populations in the world’s most regulated and highest-paying markets. For Hyderabad, which hosts the country’s densest concentration of pharmaceutical and biotechnology companies, TheraNym adds a manufacturing capability that complements the city’s existing strengths in API production, formulation, and biopharmaceutical research and development.
The Sangareddy location is strategically chosen. It lies within the Pharma City SEZ ecosystem, benefits from Telangana’s infrastructure investments in the life sciences corridor, and is accessible to the talent pool concentrated in Hyderabad’s research institutions and established pharma companies. For Aurobindo, which built its reputation on oral solid dosage generics, TheraNym marks its most consequential diversification into innovation-adjacent, high-complexity manufacturing — a transition that the company’s leadership has publicly described as generational.
Regulatory and Market Pathway
Commercial viability of TheraNym will depend on securing and maintaining regulatory approval from multiple agencies: the Central Drugs Standard Control Organisation (CDSCO) for India, the US Food and Drug Administration (US FDA), and the European Medicines Agency (EMA). CMO facilities serving global innovator clients must meet the highest tier of Good Manufacturing Practice (GMP) standards across all three jurisdictions simultaneously. The facility’s inauguration marks the beginning of that regulatory journey, not its completion. However, Aurobindo’s established track record of US FDA-approved manufacturing sites provides institutional experience in navigating multi-agency compliance — a significant operational advantage as TheraNym seeks its first commercial CMO contracts.
– Madhu Macha




